The identification of mutually exclusive somatic mutations shared among myeloproliferative neoplasm (MPN) subtypes has provided a powerful tool for studying disease evolution. Clinical features, gene mutations, and survival over 18 years were analyzed in MPN patients. One hundred thirty-eight MPN patients were subcategorized according to MPN subtypes: essential thrombocythemia (ET, n = 41), polycythemia vera (PV, n = 56), primary myelofibrosis (PMF, n = 10), and MPN unclassified (MPN-U, n = 31). Patient characteristics included clinical parameters, overall survival, and mutational status of the JAK2, CALR, and MPL genes. We compared hematologic and clinical features of JAK2 V617F -ET vs. CALR-mutated ET vs. JAK2 V617F -PV patients. JAK2 V617F -patients had higher values of erythrocytes, hemoglobin, and hematocrit compared to CALR-mutated patients (p < 0.05). The mutant allele burden in JAK2 V617F -PV and JAK2 V617F -ET patients directly correlated with erythrocyte, hemoglobin, and hematocrit values, but it inversely correlated with platelet count. Thus, mutant allele burden was an indicator of the clinical phenotype in JAK2 V617F -MPN patients. OS was not affected by the mutational status. In general, mutated JAK2, CALR, and MPL genes left specific hematological signatures. KEYWORDS: MPN; myeloproliferative neoplasm; JAK2; janus kinase 2; CALR; calreticulin;
INTRODUCTION
Myeloproliferative neoplasms (MPNs) are a group of clonal myeloid disorders that affect normal blood cell production in the bone marrow [1] [2] [3] . According to the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues, MPNs are categorized into chronic myeloid leukemia (BCR-ABL1 positive), polycythemia vera (PV), primary myelofibrosis (PMF, prefibrotic/early and overt fibrotic stage), essential thrombocythemia (ET), chronic eosinophilic leukemia (CEL), chronic neutrophilic leukemia (CNL), mastocytosis, and unclassifiable MPNs (MPN-U) [4] [5] [6] [7] [8] [9] . The most common BCR-ABL1 negative MPNs include PV, ET and PMF, while the other subtypes are rare [4] . These diseases have shared clinical features and a molecular basis [10] . Around 5% of patients suffer from progression to more advanced disease, including transformation to acute myeloid leukemia (AML) [11] .
WHO 2016 revision lists the presence of driver mutations as one of several major criteria in the diagnosis of these diseases [12] . BCR-ABL1 negative MPN patients carry driver mutations in JAK2 (Janus kinase), CALR (calreticulin) and MPL (myeloproliferative leukemia virus oncogene) genes [13, 14] . High proportion of MPN patients (75%) carries the unique JAK2 V617F mutation in exon 14; subsequently exon 12 mutations were found in 5% of patients with PV [15] . 
RESULTS

Clinical characteristics
We included 138 MPN patients, diagnosed with PV (n=41), ET (n=56), PMF (n=10) and MPN-U (n=31) in this study. Patients characteristics are shown in Supplemental Table 1 , which reports clinical parameters and mutational status of each MPN subtype at diagnosis. Median follow-up was 33 months (60 45.5, 69 and 20 months for PV, ET, PMF and MPN-U subtypes, respectively). Age at diagnosis among different MPN subtypes did not show significant differences (p>0.05). Regarding mutational analysis, three genes were analyzed: JAK2, CALR, and MPL. JAK2 V617F mutation was found in 71% of all MPN patients (Supplemental Table 1 ); CALR mutations, type 1 and 2, were detected in 13% of all MPN patients; MPL mutations, type 1 (W515L) and type 2 (W515K), were found in 4% of all MPN patients. Table 1 categorized clinical parameters of each MPN subtype at diagnosis according to the presence of JAK2 V617F , CALR, and MPL mutations.
Mutational status vs CBC in PV patients
Hematologic parameters in PV patients compared to mutational status (JAK2 V617F and JAK2 WT ) were summarized in Figure 1 . Among PV patients, the presence of JAK2 V617F mutation was associated with higher platelet count (p<0.05). However, no effect was found on clinical parameters such as WBC, RBC, Hb, Hct. WBC and RBC values were higher in JAK2 V617F PV patients, although difference was not significant.
Mutational status vs CBC in ET patients
Hematologic parameters in ET patients compared to mutational status (JAK2 V617F , JAK2 WT , CALR-mutated, CALR WT , MPL-mutated, MPL WT ) were presented in Figure 2 . RBC levels were higher in JAK2 V617F compared to JAK2 WT ET patients. Between JAK2 V617F vs CALR-mutated ET patients, JAK2 V617F mutation was present in patients with lower platelet count (p<0.05). We also categorized ET patients based on the presence or absence of driver mutations (triple negative vs patients with driver mutations) and found no significant differences in hematologic parameters.
Since PV and ET patients share JAK2 V617F mutation, we compared the clinical parameters among JAK2 V617F ET vs JAK2 V617F PV patients; we found that RBC, Hb, and Hct values were higher in PV patients t, but platelet count values were lower; however, the frequency of splenomegaly was higher (p<0.001). Interestingly, we found the same results if we compared JAK2 V617F PV patients and CALR-mutated ET patients (p<0.05).
Mutational status vs CBC in PMF patients
Hematologic parameters in PMF patients compared to mutational status were summarized in Supplemental Figure 1 . The presence of either JAK2 V617F or CALR mutation did not have an impact on analyzed clinical parameters (p>0.05). When we compared JAK2 V617F PMF, ET, and PV patients, we found that JAK2 V617F PV patients had higher RBC (p<0.001), Hb, and Hct (p<0.05) values; JAK2 V617F PMF patients had higher WBC values compared to JAK2 V617F PV and ET patients. Comparison between CALR-mutated PMF vs CALR-mutated ET patients showed that CALR-mutated PMF patients had lower Hb (p<0.05) and Plt values (p<0.001). 
Mutational status vs CBC in MPN-U patients
Driver gene MPN patients
We hypothesized that the presence of a specific mutations in JAK2, CALR, or MPL gene is the driver of MPN pathogenesis. Thus, we combined data for all PV/ET/PMF/MPN-U patients that carried JAK2 V617F mutation. Accordingly, we organized data for CALR and MPL positive MPN patients ( Figure 3 ). We found that JAK2 V617F patients had higher values for RBC, Hb, and Hct 
